title: [Trends in osteoporosis].
abstract: Monoclonal antibody inhibitors against cathepsin-K, Rank-ligand or sclerostin are the therapeutic tools of tomorrow for osteoporosis. Once-a-year infusion, for 3 years, of 5 mg zoledronate reduces the risk of vertebral and hip fractures. 5 mg-infusion of zoledronate in the 90 days following hip fracture, then annual, decreases new clinical fractures and improves survival. 150 mg-risedronate monthly has the same effects than 5 mg daily. Report of osteonecrosis of the jaw associated with bisphosphonate therapy in osteoporosis is low, less than 1/100,000. As raloxifene, basedoxifene reduces the rate of vertebral fractures. Despite its anti-fracture efficacy and safety, strontium ranelate is not available in Switzerland. We need strategies to improve patient's adherence to treatment in osteoporosis.
authors.affiliation: Service des maladies osseuses, Centre collaborateur de l'OMS pour la prévention de l'ostéoporose Département de réhabilitation et gériatrie, HUG, 1211 Genève. Brigitte.Uebelhart@hcuge.ch
authors.forename: B
authors.initials: B
authors.lastname: Uebelhart
authors.forename: R
authors.initials: R
authors.lastname: Rizzoli
mesh_terms: D050071:Bone Density Conservation Agents / Q000494:pharmacology / Q000627:therapeutic use; D002403:Cathepsins / Q000037:antagonists & inhibitors; D006801:Humans; D010010:Osteoclasts / Q000187:drug effects; D010024:Osteoporosis / Q000188:drug therapy*; D020845:Selective Estrogen Receptor Modulators / Q000494:pharmacology / Q000627:therapeutic use
chemical_list: D050071:Bone Density Conservation Agents; D020845:Selective Estrogen Receptor Modulators; D002403:Cathepsins